Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Assembly Biosciences (ASMB) over the last 11 years, with Q3 2025 value amounting to $22.5 million.

  • Assembly Biosciences' Cash & Equivalents fell 2079.99% to $22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.5 million, marking a year-over-year decrease of 2079.99%. This contributed to the annual value of $38.3 million for FY2024, which is 9325.64% up from last year.
  • As of Q3 2025, Assembly Biosciences' Cash & Equivalents stood at $22.5 million, which was down 2079.99% from $24.0 million recorded in Q2 2025.
  • In the past 5 years, Assembly Biosciences' Cash & Equivalents ranged from a high of $78.3 million in Q1 2021 and a low of $18.7 million during Q1 2024
  • Its 5-year average for Cash & Equivalents is $39.0 million, with a median of $38.3 million in 2024.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first plummeted by 6214.85% in 2023, then soared by 9325.64% in 2024.
  • Quarter analysis of 5 years shows Assembly Biosciences' Cash & Equivalents stood at $45.6 million in 2021, then increased by 14.88% to $52.4 million in 2022, then crashed by 62.15% to $19.8 million in 2023, then skyrocketed by 93.26% to $38.3 million in 2024, then plummeted by 41.23% to $22.5 million in 2025.
  • Its last three reported values are $22.5 million in Q3 2025, $24.0 million for Q2 2025, and $23.4 million during Q1 2025.